Trinity Webinar
China NRDL 2025:
Locked Out or Leveled Up?
Winning China Access in the NRDL and CIIDL Era
Available On Demand
Meet Our Trinity Experts
Pricing pressure is rising but so are new opportunities.
China’s 2025 NRDL update continues to demonstrate constrained willingness to pay while still rewarding truly differentiated therapies. Meanwhile, the emergence of a Commercial Insurance Innovative Drug List (CIIDL, formerly Category C) is creating an alternative access route for highly innovative therapies to preserve price and achieve targeted access.
This evolving dual-track access system is forcing manufacturers to rethink how and where they compete.
In this session, you will:
Understand the key takeaways from the 2025 NRDL update, including inclusion trends and pricing dynamics
Explore how oncology, rare disease, and chronic condition products performed, including analogues that achieved premium prices through clinical differentiation
Learn how China’s commercial drug list is emerging as a viable funding pathway for high-cost innovations, including cell therapies and Alzheimer’s treatment
Discuss how to strategically navigate NRDL and commercial pathways in launch and lifecycle planning
Unpack the latest NRDL negotiation outcomes and explore what the expanding CIIDL pathway means for future access strategies.
This webinar is designed for teams that own pricing, access, and launch decisions for China, including global and regional market access and pricing leaders and commercial and portfolio strategy teams focused on oncology, rare disease, and specialty therapies.
Watch Now
By clicking "I agree" above, you are agreeing that Trinity will use and protect your personal data in accordance with our Privacy Policy. You can opt out of future marketing communications at any time by clicking the unsubscribe link at the bottom of any marketing email you receive from Trinity.